In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs

Barry R. Campbell, Dinko Gonzalez Trotter, Catherine D.G. Hines, Wenping Li, Manishkumar Patel, Weisheng Zhang, and Jeffrey L. Evelhoch

Barry R. Campbell is an Associate Principal Scientist in Translational Biomarkers at Merck Research Laboratories in Kenilworth, New Jersey. Dinko Gonzalez Trotter, PhD, is a Senior Director in Early Clinical Development at Regeneron Pharmaceuticals, Inc., in Tarrytown, New York. Catherine D. Hines, PhD is a Director in Translational Biomarkers at Merck Research Laboratories in West Point, Pennsylvania. Manishkumar Patel, PhD is a Principal Scientist in Translational Biomarkers at Merck Research Laboratories in West Point, Pennsylvania. Weisheng Zhang is a Senior Principal Scientist in Translational Biomarkers at Merck Research Laboratories in Boston, Massachusetts. Jeffrey L. Evelhoch, PhD, is Vice President of Translational Biomarkers at Merck Research Laboratories in West Point, Pennsylvania.

Address correspondence and reprint requests to Jeffrey L. Evelhoch, Merck Research Laboratories, 770 Sumneytown Pike, Mailstop: WP42-211, West Point, PA 19486 or email: jeffrey.evelhoch@merck.com.

Abstract

It is well understood that the biopharmaceutical industry must improve efficiency along the path from laboratory concept to commercial product. In vivo imaging is recognized as a useful method to provide biomarkers for target engagement, treatment response, safety, and mechanism of action. Imaging biomarkers have the potential to inform the selection of drugs that are more likely to be safe and effective. Most of the imaging modalities for biopharmaceutical research are translatable to the clinic. In vivo imaging does not require removal of tissue to provide biomarkers, thus reducing the number of valuable preclinical subjects required for a study. Longitudinal imaging allows for quantitative intra-subject comparisons, enhancing statistical power, and further reducing the number of subjects needed for the evaluation of treatment effects in animal models. The noninvasive nature of in vivo imaging also provides a valuable approach to alleviate or minimize potential pain, suffering or distress.

Key words: drug development; imaging; target engagement; treatment response; drug safety; mechanism of action; 3Rs

Introduction

Healthcare costs have increased at an alarming rate over the past 5 decades. Spending for healthcare in the United States relative to the gross domestic product increased from 5.0% in 1960 to 17.5% in 2014 (Centers for Medicare & Medicaid Services 2015c) and is projected to increase to 19.6% by 2024 (Centers for Medicare & Medicaid Services 2015b). The high costs of developing more effective and safer therapies, recently estimated at 1.4 billion US dollars per approved new compound (DiMasi et al. 2016), reflect an industry-wide 10.4% success rate from first-in-human studies comprised 9.8% of U.S. spending for healthcare in 2014 (Centers for Medicare & Medicaid Services 2015a) and are projected to increase to 10.4% by 2024 (Centers for Medicare & Medicaid Services 2015b).
to approval (Hay et al. 2014). Moreover, much of the failure occurs in Phase 2 (32% success rate) and Phase 3 (60% success rate) clinical trials (Hay et al. 2014), where costs are substantial (Paul et al. 2010). The main reasons for attrition are safety and lack of efficacy, which respectively accounted for 28% and 56% of molecules failing in Phase 2 or Phase 3 from 2011 to 2012 (Arrowsmith and Miller 2013). The ability to identify molecules with insufficient efficacy or safety issues prior to late-phase clinical development would reduce the costs and increase the rate of developing new therapeutics.

Over a decade ago, both industry (Colburn 2000) and regulators (Food and Drug Administration 2004) recognized that a new approach, taking advantage of advances in scientific and technical methods, was needed to improve efficiency along the path from laboratory concept to commercial product. The approval of 45 new drugs in 2015, the highest number approved since 53 were approved in 1996 (Mullard 2016), indicates that this new approach may be having an impact. One of the key elements in this new approach is the use of biomarkers, which are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention (Biomarkers Definition Working Group 2001). In vivo imaging, when used appropriately, can provide biomarkers that supply information about biochemical, physiological, and anatomic processes. Information from imaging biomarkers in preclinical studies (i.e., target engagement, treatment response, safety, or mechanism of action) can have a critical impact on internal decision-making to help increase the odds of success for drugs taken into the clinic.

The ability of in vivo imaging to provide biomarkers without requiring surgery or euthanization to remove tissues also impacts the humane use of animals in pharmaceutical development. The guiding principles underpinning the humane use of animals in scientific research, introduced by Russell and Burch in 1959 (Russell and Burch 1959), are commonly known as the 3Rs, referring to replacement, reduction, and refinement in the use of animals. Replacement indicates changes in an experimental protocol to use alternative techniques (e.g., an in silico model) in place of animals. Reduction signifies approaches to obtain information from fewer animals or more information from the same number of animals, thereby reducing the number of animals needed to get information from an experiment. Refinement denotes modifications in the way experiments are carried out that minimize the actual or potential pain, distress, and other adverse effects experienced by the animals. Although in vivo imaging by definition involves animals and hence cannot replace animal use, it can both reduce and refine their use.

The use of in vivo imaging contributes to reduction in the number of animals used in preclinical drug development, because it allows repeated measurements to be made in the same animal. To longitudinally assess a treatment effect, other methods often require separate groups of animals to be euthanized so that measurements can be made for each study time point in each treatment group. Using in vivo imaging, because each animal can be evaluated at multiple time points, one group of animals can be used for all time points in each treatment group. By imaging animals prior to initiation of treatment, each animal serves as its own control. Hence, measurements at all time points for each animal using in vivo imaging not only reduce the number of animals, it also eliminates the impact of variability between animals in each time point group, thereby increasing statistical power. Moreover, animals can be assigned to treatment groups based on baseline characteristics to minimize differences between treatment groups at baseline.

The noninvasive nature of in vivo imaging also provides a valuable tool for refinement, both when imaging is used to provide a biomarker and to facilitate other measurement methods. When imaging is used to provide a biomarker, it often replaces methods requiring removal of tissue, thereby minimizing pain and distress of the animals. In some instances where the imaging procedures are short in duration, minimal or no anesthesia is required further minimizing the animal’s distress. Examples of the use of imaging to facilitate other measurement methods are the use of ultrasound imaging to guide the placement of a telemetry probe for blood pressure measurements (Campbell et al. 2008) and the use of magnetic resonance imaging (MRI) to guide intracranial delivery of therapeutics or for neurochemical sampling (Chen et al. 2015). In both instances, optimal placement is critical to acquire accurate reproducible data and improves animal quality of life by minimizing long-term adverse effects of inaccurate placement.

The methods used in preclinical studies are also available for clinical studies for most of the imaging modalities used in drug development. Consequently, the relationships between drug dose or exposure and target engagement, treatment response, or safety established in preclinical studies can be translated to studies in humans. The preclinical data provide a target for the magnitude of effects that should be observed in the clinical study if the drug is acting as it did in the preclinical model(s). Conversely, clinical imaging data can help to evaluate which animal model most closely reflects disease and the impact of treatment on the disease in humans.

**Imaging Modalities Used in Drug Development**

Ultrasound imaging (also known as ultrasonography [US]) uses high frequency sound waves, outside the audible range of humans, to visualize structures of internal organs and their functions in both clinical and preclinical research and diagnostics (Cobbold 2007). Ultrasonic waves are delivered to tissues by an ultrasonic transducer, and the echoes that are reflected from tissues are detected via the same transducer. The time and strength of the echoes received by the probe, which are directly related to the position and density of tissues, are converted into pixels and displayed in an ultrasonic image. US is frequently used to see internal body structures such as tendons, muscles, joints, vessels, and internal organs and can assist in diagnosis of a disease and exclusion of suspicious pathology as well as assess response to treatment. In addition to the most commonly used B-mode cross-sectional structure image, US can also display the rate and direction of blood flow, the motion of tissue over time, and the stiffness of tissue as well as presence of specific molecular targets in blood vessels using microbubble contrast agents (Mulvagh et al. 2000). US is an economically efficient imaging approach and provides good contrast in most cardiovascular and abdominal tissues. Disadvantages of US include inter-operator variability and the difficulty of imaging tissues through bone or air.

Computed tomography (CT), also referred to as a computerized axial tomography, is an X-ray-based imaging modality that produces detailed three-dimensional (3D) images (Romans 2011). X-rays penetrate samples and, depending on the properties of the sample, are attenuated as they traverse the sample to provide contrast. In a biological subject, bones attenuate X-rays the most, soft tissue next, and air the least. A CT scanner rotates opposing pairs of X-ray sources and detectors around the
subject, and a 3D image is reconstructed using a powerful computer. Bone, lung (air), and fatty tissues can be easily identified, allowing scientists to monitor disease progression and evaluate therapeutic responses in vivo over time noninvasively with high accuracy and repeatability. Due to poor inherent contrast between soft tissues, contrast materials such as intravenous iodinated contrast agents and orally administered barium sulfate are employed to better visualize heart, vasculature, brain, kidney, liver, gastrointestinal track, and tumors. In addition, since samples are subjected to a dose of ionizing radiation about 300 to 1000 times of conventional X-ray, for in vivo studies, the resulting increased risk of cancer and impact on proliferative tissues may need to be considered [Frush and Applegate 2004].

MRI is also commonly used to visualize tissues in animals and humans (Bushong 2003). MRI harnesses the magnetic properties, also known as spin, of the nucleus of hydrogen atoms contained in water and fat within tissues. When a strong magnetic field is applied to the body, the hydrogen spins act as little magnets and align with the direction of the magnetic field. A short radiofrequency pulse is applied to knock the hydrogen spins out of alignment. When the radio waves are turned off, the hydrogen spins realign, sending out radiofrequency signals. These signals provide information about the location and amount of the hydrogen spins in the body, which can be used to reconstruct a 3D image. In addition to water and fat content, the MRI signal can also be affected by the local microscopic magnetic environment, which varies from tissue to tissue and contributes to the excellent diverse soft tissue contrast in MRI. The MRI signal can be made sensitive to vascular flow (Srichai et al. 2009), to assess the dynamics and spatial distribution of blood flow within a vascular structure of interest, or diffusion (Le Bihan 2003), which informs on microscopic tissue architecture. MRI contrast agents, most commonly gadolinium-based, are also used to improve the visibility of internal body structures and vasculature and can provide functional information of specific tissues (O’Connor et al. 2012). In addition, functional MRI leverages blood flow and oxygenation changes during neuronal activation of different brain regions to visualize neural responses to external stimuli (Logothetis 2008). The length of time required for MRI acquisitions limits experimental throughput relative to optical, US, and CT.

Positron emission tomography (PET) and single-photon emission CT are nuclear imaging techniques that provide molecular information about tissue and organ function (Jaszczak and Coleman 1985; Wahl and Robert 2008). PET is based on detection of 2 photons emitted in opposite directions resulting from annihilation of a positron during the decay of a positron-emitting radioisotope. $^{11}$C, $^{18}$F, and $^{68}$Ga are among the radioisotopes most frequently used to label molecules, which are commonly referred to as PET tracers because only a subphysiologic (trace) amount is needed to generate PET images. PET tracers designed to bind to specific proteins (often transmembrane receptors or enzymes) are also known as radioligands. After administration of a PET tracer into the body, a PET scanner measures its distribution by detecting the emitted photons in coincidence and reconstructing a 3D image. PET images can provide information about target occupancy, metabolism, and gene expression as well as bio-distribution of radiolabeled compounds. PET is often used in combination with CT or MRI to precisely co-register the PET images that convey molecular information with the anatomical location. Radiation exposure is inherent to the technology, limiting the number of repeat scans that can be performed on the same subject. The difficulty and cost of developing, producing, and transporting radiotracers are also limiting factors.

Optical imaging includes bioluminescence imaging (BLI), fluorescence imaging, and optical coherence tomography (OCT) (Weissleder et al. 2010). BLI is based on detection of visible light produced by reaction of a substrate (e.g., luciferin) with an enzyme (e.g., luciferase) expressed in genetically manipulated cells within living animals. Luciferases are found in many organisms, with firefly and click beetle luciferases most commonly used for in vivo imaging. Firefly luciferase catalyzes the light-producing reaction by oxidizing the substrate D-luciferin in the presence of oxygen and other cofactors such as ATP and magnesium (Wilson and Hastings 1998). The bioluminescence signal can be captured by an in vivo imaging system equipped with a very sensitive camera. As a genetic reporter, the luciferase gene can be incorporated into cells to track cell proliferation and trafficking, gene expression, biological pathway, and protein degradation as well as protein-protein interaction (Ozawa et al. 2013). BLI is sensitive, quantitative, cost effective, and has higher throughput than other imaging modalities; therefore it greatly increases the speed of preclinical research. However, translation of BLI into the clinic is limited by the requirement of genetic manipulation and attenuation of light from tissues.

In vivo fluorescence imaging also uses a sensitive camera to detect fluorescence emitted from fluorophores in small animals after exposure to light excitation. Exogenous near-infrared fluorescence probes can be designed to reflect different biological processes and tissue functions based on target specific binding, enzyme-specific activation, and tissue distribution (Ozawa et al. 2013). To detect fluorescence signals, subjects are administered with the probe, and external excitation light is delivered to the region of interest. The fluorophore absorbs an excitation photon and emits a longer wavelength photon, which is detected by a sensitive camera. Autofluorescence background, light scattering, and absorbance of tissues are inherent challenges in this technology. Current applications are mainly focused on small animals, with growing clinical applications in image-guided surgery (Allison 2016).

OCT is an optical imaging technique used to capture micrometer-resolution 3D images just below the surface in biological tissues. OCT applies an echo technique, similar to US, using light instead of sound to detect the reflection of light from an object. Light is split into 2 paths: a reference mirror and the tissue. A small portion of the light that reflects from subsurface tissue is combined with the reference light from the reference arm, resulting in an interference pattern, which contains the spatial dimensions and location of structures of tissue. Light scattering from opaque biological tissues limits the depth of OCT to 1 to 2 mm. Although it is used in preclinical studies, its primary use is in the clinic to detect high-resolution structures of the eye to assess axonal integrity in multiple sclerosis, macular degeneration, progression of glaucoma, and diabetic macular edema (Kostanyan et al. 2015).

Use for Target Engagement

Teams in the pharmaceutical industry focused on discovery and development of drugs for targets in the central nervous system have long recognized the value of target engagement for increasing confidence, guiding dose selection, and reducing risk at key stages of the discovery and development process (Honer et al. 2014). PET provides a noninvasive, quantitative measure of target (e.g., receptor, enzyme, ion channel) distribution in tissues using a radioligand with high affinity and selectivity for the specific target of interest. Target binding site
density (location and amount) is assessed by kinetic modeling of PET tracer distribution over time in specific regions of interest (i.e., previously defined anatomic regions that may be known to be target-rich or target-deficient based on in vitro studies) derived from dynamic PET data and from the PET tracer concentration in arterially sampled blood (Carson 2005).

PET target engagement studies are typically conducted by following a baseline PET scan, which uses only the radioligand to assess baseline target density, with a second scan in the same animal where the radioligand is administered after a test drug. In target-rich regions, the amount of target measured by the radioligand is lower in the PET scan after test drug administration compared to the baseline PET scan if the test drug competes with the radioligand for the target (Cunningham et al. 2004). Assessment of the change in amount of target in specific regions of interest before and after drug provides a quantitative assessment of target occupancy (Finnis et al. 2007). Each pair of baseline and post-drug PET scans provides one value for occupancy at the exposure (dose) of the test drug. A dose- or exposure-to-occupancy relationship is obtained from a group of subjects receiving baseline and post-drug PET scans at various drug exposures and/or administering the radioligand at different times post-drug administration. The use of PET to determine such exposure-to-occupancy relationships has a significant impact on reduction and refinement, because the same animal can be evaluated and recovered in drug occupancy PET studies multiple times. Previously, such relationships were determined from terminal animal studies where drug occupancy is assessed by ex vivo measurement of radioligand binding.

A recent example of the use of PET for evaluating target engagement is provided by [11C]MK-8193, which is a PDE10A-specific PET tracer (Cox et al. 2015). Inhibition of PDE10A, which enhances striatal output by increasing activity in the cGMP and cAMP signaling pathways (Siuciak et al. 2006), is a target being developed for the potential to provide efficacy on positive, cognitive, and negative symptoms of schizophrenia (Jan and Jacob 2011). Studies in rhesus monkeys (Figure 1) demonstrate that highest radioligand uptake is in the striatum, with very low retention in all other brain regions, and that THPP-1, a potent PDE10A inhibitor (Smith et al. 2013), engaged with the molecular drug target. Further studies in rhesus monkeys and rats (Hostetler et al. 2015) demonstrated similar target occupancy curves for THPP-1 in both species (Figure 2), although this is not always the case.

Combination of target occupancy curves with efficacy data from preclinical studies can establish a suitable range of exposures for testing in clinical studies and ensure that target engagement is sufficient when the clinical proof of concept trial is conducted. If the proof of concept trial is positive, the dose-occupancy information can be used to maximize efficacy while minimizing associated side effects. On the other hand, if sufficient target occupancy levels are obtained and the outcome of the proof of concept trial is negative, a clear decision can be made that the mechanistic hypothesis for the therapeutic approach is invalid. The development of neurokinin 1 (NK1) receptor antagonist provides a good example of both cases. When evaluated in clinical trials for treatment of depression (Keller et al. 2006) or anxiety (Michelson et al. 2013), the NK1 antagonist L-759274 showed no statistically significant differences from placebo. Because clinical PET receptor occupancy studies with [18F]SPARQ (Keller et al. 2006) indicated that the doses used in these studies achieved very high occupancies that effectively blocked the NK1 receptor system in the brain continuously throughout the study period, confidence that the proof of concept was adequately tested led to the decision to stop pursuing those indications. However, for prevention of acute and delayed chemotherapy-induced nausea and vomiting, aprepitant, a selective NK1 antagonist, was effective (Hargreaves et al. 2011). In this case, PET studies were used to pick the lowest dose that demonstrated full central nervous system target engagement, thereby optimizing the therapeutic window and minimizing potential drug-drug interactions associated with complex drug regimens used in oncology.

**Use for Treatment Response**

Therapeutic efficacy is often linked to changes in tissue gene expression, biochemistry, physiology, and/or morphology in response to the drug. These pharmacodynamic (PD) effects may follow a dose-response relationship and may precede a therapeutic benefit. The objective measurement of these PD effects can lead to biomarker candidates with preclinical and clinical applicability (Frank and Hargreaves 2003). Expression of pharmacological activity commensurate with target engagement increases confidence that the hypothesized therapeutic mechanism is adequately being tested (Morgan et al. 2012).

Biomarkers may be based on the PD effect of compounds on blood chemistry, making repeat measurements practical. For instance, the dose-dependent effect of statins on HMG-CoA reductase is readily reflected by decreases in circulating LDL cholesterol (Nissen et al. 2005). In some instances, however, there may not be a systemic measure of a PD effect at the site of action, and the molecular target may be constrained to a specific deep tissue or organ system. In those situations, it may be necessary to assess the PD effect at the site of action. The direct measurement of a biomarker in tissue may require necropsy in the case of animal models or biopsy in clinical cases. Imaging allows noninvasive and longitudinal measurements of tissue properties in vivo. The following 2 examples show how imaging has a direct impact on the principle of reduction in animal research, specifically in the context of the measurement of PD effects.

Genetically engineered mouse models are crucial for testing of candidate targeted therapeutic compounds. Genetically engineered mouse models are often difficult to produce and expensive, and their availability may be limited due to complex

---

**Figure 1.** Summed PET images (30-90 min) of [11C]MK-8193 in rhesus monkey brain overlaid on MRI under baseline conditions (A) and after administration of THPP-1 (B). The baseline PET study shows high tracer retention (red color) in the striatum. Tracer binding in the striatum is blocked after administration of THPP-1. Scale is in SUV (standardized uptake value).

[Reprinted from Cox CD, Hostetler ED, Flores BA, Evelhoch JL, Fan H, Gantert L, Holahan M, Eng W, Joshu A, McGaughy E. 2015. Discovery of [11C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors, Bioorganic Medical Chemistry Letters, with permission from Elsevier.]
breeding. In the case of the K-rasLSL-G12D and K-rasLSL-G12D/p53LSL-R270H models (Olive et al. 2004), Adeno-Cre viral activation leads to the development of lung tumors. Tumors may develop at a highly variable rate, deep in the body, making size measurements that rely on traditional caliper techniques impossible in vivo. Necropsy must therefore be used to monitor tumor progression and regression due to pharmacologic intervention. Haines et al. (2009) demonstrated the use of micro x-ray CT to perform volumetric lung tumor measurements in K-rasLSL-G12D and K-rasLSL-G12D/p53LSL-R270H mice, showing that this novel technique can be used to monitor both tumor progression and dose-dependent response to treatment with Erlotinib (see Figure 3). This high-throughput micro x-ray CT imaging approach provided real-time in vivo quantitative baseline evaluation of tumor burden of all mice in the study across several time points after viral induction and enabled same-subject monitoring of tumor inhibition.

Abnormally highly expressed molecular cell surface markers are often a distinguishing feature of malignancies. Imaging of tumor molecular cell surface targets using PET radioligands is feasible in animal models and in the clinic. Epidermal growth factor receptor family member ErbB-2 (HER-2) is a cell surface protein with a prominent signaling role in a significant percentage of breast cancers (Slamon et al. 1987). HER-2 is a client protein of the molecular chaperone heat shock protein 90 (HSP90), which confers stability to HER-2, making HSP90 a potential therapeutic target (Banerji 2009). Smith-Jones et al. (2004) demonstrated that HSP90 inhibition could be monitored in a murine xenograft model by PET imaging of HER-2 expression using a 68Ga labeled F(ab′)2 radiotracer. Noninvasive PET imaging of HER-2 expression enabled the in vivo exploration of dynamic loss and recovery of tumor HER-2 expression following HSP90 inhibition. Furthermore, PET imaging enabled time-dependent measurements in vivo in the same subject (see Figure 4), minimizing the number of animals required by allowing pair-wise comparisons of changes in the HER-2 PET signal due to HSP90 inhibition, which increased the statistical power. Based on these findings, it was hypothesized that PET imaging of HER-2 could be used as a downstream PD measure of HSP90 inhibition in a clinical setting. The anti-HER2 antibody Trastuzumab, labeled with the 89Zr PET radioisotope, was subsequently used to confirm the clinical target inhibition of HSP90 in metastatic breast cancer patients (Gaykema et al. 2014).

Figure 2. Plasma concentration vs PDE10A enzyme occupancy relationship in a monkey brain and b rat brain for THPP-1 as determined by PET studies with [11C]MK-8193. [Reprinted from Hostetler ED, Fan H, Joshi AD, Zeng Z, Eng W, Gantert L, Holahan M, Meng X, Miller P, O’Malley S, Purcell M, Riffel K, Salinas C, Williams M, Ma B, Ruist N, Smith SM, Coleman PJ, Cox CD, Flores BA, Raheem IT, Cook J, Evelhoch JL. 2015. Preclinical characterization of the phosphodiesterase 10A PET tracer [11C]MK-8193, Mol Imaging Biol, with permission of Springer.]

Figure 3. Visualization of lung tumor development in K-rasLSL-G12D/p53LSL-R270H (KP) models. Panel 1: Example of CT images of a control KP mouse with no tumor and H&E stain. Panel 2: Example of CT images of a KP mouse infected with a high dose of Adeno-Cre virus with isolated lung tumors and H&E stain. Panel 3: Example of CT images of a KP mouse infected with a high dose of Adeno-Cre virus with small multifocal tumors and H&E stain. [Reprinted from Haines BB, Bettane KA, Chenard M, Sevilla RS, Ware C, Angagaw MH, Winkelmann CT, Tong C, Reilly JF, Sur C, Zhang W. 2009. A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models, Neoplasia, with permission from Elsevier.]
Multiple imaging modalities have the ability to assess potential safety-related treatment effects in drug development. Many preclinical imaging protocols are adapted from established clinical protocols or published animal experiments to not only ensure the translatability of the techniques for assessment, but also to further ensure that accepted and reliable methodologies are being used. First, imaging can be a powerful de-risking tool, where direct or indirect effects due to treatment are measured. While de-risking studies appear similar to PD or efficacy studies, the treated animals are normal, healthy animals such that any undesired observed effects can be attributed solely to treatment effects and represent safety risks. As such, imaging typically answers de-risking questions involving the presence or absence of an effect, dose dependence of the effect, and the potential reversibility of this effect. Second, imaging can be used to generate new, noninvasive safety biomarkers. The presence of a direct or indirect effect can be used as a biomarker if the effect is sensitive and specific to the treatment, reliable, and shows dose dependence. To begin developing these safety biomarkers, animals must be treated with a molecule known to induce a detectable effect and monitored with an appropriate imaging modality.

MRI, CT, and US are more routinely accessible and available as preclinical imaging modalities in assessing safety-related treatment effects. 3D techniques such as MRI and CT allow for accurate volume measurements, which can serve as a surrogate measure for organ weight. As mentioned earlier, MRI provides excellent soft tissue contrast and can consequently provide volume measurements of soft tissue, such as in brain regions. Posaconazole IV Solution (POS IV), a potent, selective triazole antifungal approved for use in adult patients, was found to enlarge the lateral ventricles of the brain in 5 of 8 juvenile preweaning dogs during necropsy at the conclusion of a 6-week dosing period. To determine if this was a treatment effect to support the administration of POS IV in children 2 years and older and in adults 18 years and older, Hines et al. (2015) used MRI to measure the volumes of dog brain ventricles before and during 12 weeks of treatment with POS IV. In a study using 36 juvenile and 16 adult dogs, POS IV had no effect on ventricle volume at any timepoint during dosing in either the adult or the juvenile dogs. In this study, the ability to classify the animals’ ventricle size at baseline (Figure 5) so that animals that were obviously different from the rest of the cohort were not included in a single group, which would skew the results of the study, and to distribute the sizes of ventricles between groups as best as possible was critical to rigorous evaluation of a potential treatment effect. Two-dimensional US and 3-dimensional CT techniques can similarly assess area or volume, respectively, to equally distribute effects between treatment groups. CT imaging is used routinely for bone assessment, as metals such as calcium increase X-ray attenuation. As such, bone mineral density measurements can quantify the amount of bone loss or gain due to treatment (Williams et al. 2013). CT has also been used to evaluate developing bone in response to reproductive toxicants (Wise et al. 2013; Wise et al. 2010). Lastly, US is a mobile and rapid measurement that can provide high-throughput assessment compared to MRI and CT. Similar to MRI, US can also assess soft tissues easily. Preclinical cardiac US (echocardiography) is highly translatable to the clinic for cardiac de-risking, for example, in providing functional contractility or blood flow information. Finally, as MRI, US, and CT imaging can be used to monitor treatment effects during studies, recovery of these effects can also be monitored to determine the permanence of treatment or return animals to colonies, for example, thereby promoting the 3Rs. For example, Lenhard et al. (2016) applied dynamic contrast-enhanced MRI to detect changes in hepatobiliary transporter function as a result of amiodarone-induced hepatic phospholipidosis before, during, and 2 weeks after cessation of amiodarone treatment. The calculated rates of contrast agent wash-out, which is dependent on efflux transporter function, decreased with treatment and fully recovered after cessation of treatment. These results demonstrated the ability to monitor drug-induced liver injury using novel clinically translatable biomarkers in a preclinical setting.

Additionally, PET can be used for noninvasive safety assessment, although this modality is less routinely used due to the increased logistics involved with radioisotopes, radiochemistry, and sensitive timing. Similarly, optical imaging can be used for safety assessment applications but is often limited by its depth-dependent nature. However, OCT has recently been successfully applied to address ophthalmic toxicity (Fielden et al. 2015) and has the additional benefit of being directly translatable to the clinic.

**Use for Mechanism of Action**

Mechanism of action (MoA) can be defined as the biochemical interaction through which a drug produces its effect. With imaging, this can be measured from the cell level to organ level and all the way to the animal level. Use of reporter genes has allowed researchers to probe the MoA of receptors via signal transduction cascades at the cell level. These assays are typically refined in vitro and then translated to the animal level using transgenic mice or simply using tumor-bearing mice. In one study, reporter gene imaging was used to monitor activation of the Erb2/Her2/neu pathway during radiotherapy (Wolf et al. 2011). Using a split luciferase model, they were able to develop and refine a method based on the MoA of Erb2 signal transduction that could be used to screen compounds that interfere with Erb2 activation in cell culture. The same cells were then used to create tumor-bearing mice that could be

![Figure 4. MicroPET images (coronal slice and transverse slice through tumor and kidneys) of 2 different nude mice with single BT-474 tumors.](image-url)
used to monitor Erb2 activation. Since the same animals could be monitored before, during, and after treatment, the number of animals needed to screen potential drug candidates was reduced.

More specific modes of action of a disorder can be visualized through the use of reporter genes, which then can be used to determine dose response, dose selection, and needed drug levels to produce MoA and therapeutic response. Polycythemia vera is a disorder in which a somatic mutation of the gene encoding JAK2 causes myeloproliferation (James et al. 2005). The same mode of action can be recapitulated in mice when bone marrow expressing the mutation is used to reconstitute irradiated mice (Wernig et al. 2006). A luciferase-based model was developed in which cells expressing the mutation could be monitored using in vivo BLI (Ma et al. 2009). This made it possible to examine the kinetics of disease regression and regression noninvasively. Since the same animals were scanned at multiple time points, the numbers of animals for the study were reduced. The results led to the development of an intermittent dosing schedule that achieved significant reductions in both erythroid and myeloid populations with minimal impact on lymphoid cells. This provided a rationale for the use of noncontinuous treatment to provide optimal therapy for PV patients (Kraus et al. 2012).

Conclusions

Improved ability to identify molecules with insufficient efficacy or safety issues prior to late-phase clinical development is needed to reduce the costs and increase the rate of developing new therapeutics. In vivo imaging can provide information in preclinical studies (i.e., target engagement, treatment response, safety, or mechanism of action) that has a critical impact on internal decision-making to help increase the odds of success for drugs taken into the clinic.

Most of the imaging modalities used in preclinical studies translate to the clinic. The number of preclinical subjects required for a study is reduced, because in vivo imaging does not require surgery or euthanasia to obtain the desired information. The number of subjects needed for the evaluation of treatment effects in animal models is further reduced by the ability of imaging to provide quantitative intra-subject comparisons that enhance statistical power. The noninvasive nature of in vivo imaging can also help to alleviate or minimize potential for pain or distress in research animals.

Acknowledgments

The authors thank Drs. Eric Hostetler, Cyrille Sur, Richard Kennan, Michael Klimas, and Joseph DeGeorge for their insightful feedback.

References

Allison RR. 2016. Fluorescence guided resection (FGR): a primer for oncology. Photodiagnosis Photodyn Ther 13:73–80.

Arrowsmith J, Miller P. 2013. Trial watch: phase II and phase III attrition rates 2011–2012. Nat Rev Drug Discov 12(8):569.

Banejji U. 2009. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15(1):9–14.

Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95.

Bushong SC. 2003. Magnetic Resonance Imaging: Physical and Biological Principles. St. Louis, MO: Mosby.

Campbell BR, Bunzel MM, Zhang C, Shen X, Ahn C, Johnson CV, Cai T-Q, Walker M. 2008. A novel approach to telemetry blood pressure probe placement in mice using high frequency micro-ultrasound guided surgery. FASEB J 22(2 Supplement):11.

Carson RE. 2005. Tracer kinetic modeling in PET. In: Bailey DL, Townsend DW, Valk PE, Maisey MN, eds. Positron Emission Tomography: Basic Sciences. London: Springer London. p. 127–159.

Centers for Medicare & Medicaid Services. 2015a National health expenditures by type of service and source of funds: calendar years 1960–2014 [Internet]. Available online https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/NHE2014.zip, accessed on November 5, 2015.
Centers for Medicare & Medicaid Services. 2015b NHE projections 2014–2024 - Tables [Internet]. Available online https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/Proj2014Tables.zip, accessed on November 5, 2015.

Centers for Medicare & Medicaid Services. 2015c NHE summary including share of GDP, CY 1960–2014 [Internet]. Available online https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/NHEGDP14.zip, accessed on November 5, 2015.

Chen A, Hines CD, Song X, Kuruvilla S, Farris G, Markgraf PJ. 2012. Magnetic resonance imaging assessment of the ventricular system in the brains of adult and juvenile beagle dogs treated with posaconazole IV solution. J Pharmacol Toxicol Methods 76:55–64.

Chen A, Hines CD, Song X, Kuruvilla S, Farris G, Markgraf PJ. 2012. Magnetic resonance imaging assessment of the ventricular system in the brains of adult and juvenile beagle dogs treated with posaconazole IV solution. J Pharmacol Toxicol Methods 76:55–64.

Chen A, Hines CD, Song X, Kuruvilla S, Farris G, Markgraf PJ. 2012. Magnetic resonance imaging assessment of the ventricular system in the brains of adult and juvenile beagle dogs treated with posaconazole IV solution. J Pharmacol Toxicol Methods 76:55–64.

Chen A, Hines CD, Song X, Kuruvilla S, Farris G, Markgraf PJ. 2012. Magnetic resonance imaging assessment of the ventricular system in the brains of adult and juvenile beagle dogs treated with posaconazole IV solution. J Pharmacol Toxicol Methods 76:55–64.

Chen A, Hines CD, Song X, Kuruvilla S, Farris G, Markgraf PJ. 2012. Magnetic resonance imaging assessment of the ventricular system in the brains of adult and juvenile beagle dogs treated with posaconazole IV solution. J Pharmacol Toxicol Methods 76:55–64.
